UTRECHT, The Netherlands, and PHILADELPHIA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” or the “Company”), a clinical-stage immuno-oncology company historically focused on its proprietary Gammabody® bispecific gamma delta T cell engagers, today announced financial results for the second quarter ended June 30, 2025 and provided a corporate update.
Related Questions
How did LAVA's Q2 revenue and earnings compare to consensus expectations?
What guidance did the company provide for Q3 and full-year 2025 revenue and net loss?
What is the current cash runway and burn rate, and when will the company need additional financing?
What are the key milestones for the Gammabody® bispecific program in the next 12 months (e.g., IND filings, trial initiations, data readouts)?
Are there any upcoming regulatory or clinical milestones that could act as catalysts (e.g., FDA meetings, trial enrollment milestones)?
How does the company's cash burn rate compare to peers in the immuno‑oncology space?
What are the recent trends in the company's share price and trading volume around the release?
Did the company announce any partnership, licensing or collaboration deals that could affect future revenue streams?
How does LAVA's valuation (P/E, EV/Revenue, etc.) compare to other clinical‑stage immuno‑oncology companies?
What is the outlook for the company's pipeline beyond the Gammabody platform (e.g., additional candidates, platform extensions)?
What is the expected impact of the announced corporate update on analyst sentiment and target price revisions?
Are there any disclosed risks or uncertainties (e.g., regulatory, clinical, financing) that could affect the stock's downside risk?